Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
STE Stock Forecast 2026-2027
$214.57
Current Price
$21.06B
Market Cap
Buy 6
Hold 2
Sell 1
Wall St Analyst Ratings
Distance to STE Price Targets
+39.8%
To High Target of $300.00
+36.6%
To Median Target of $293.00
+7.7%
To Low Target of $231.00
STE Price Momentum
-6.9%
1 Week Change
-13.6%
1 Month Change
-5.3%
1 Year Change
-15.4%
Year-to-Date Change
-20.4%
From 52W High of $269.44
+4.7%
From 52W Low of $204.90
📊 TOP ANALYST CALLS
Did STE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if STERIS is one of their latest high-conviction picks.
Latest STE Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, STE has a bullish consensus with a median price target of $293.00 (ranging from $231.00 to $300.00). The overall analyst rating is Buy (7.8/10). Currently trading at $214.57, the median forecast implies a 36.6% upside. This outlook is supported by 6 Buy, 2 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
STE Analyst Ratings
6
Buy
2
Hold
1
Sell
STE Price Target Range
Low
$231.00
Average
$293.00
High
$300.00
Current: $214.57
Latest STE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for STE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 8, 2025 | Morgan Stanley | Patrick Wood | Overweight | Maintains | $295.00 |
| Jul 22, 2025 | Keybanc | Brett Fishbin | Overweight | Maintains | $288.00 |
| Jul 15, 2025 | Morgan Stanley | Patrick Wood | Overweight | Upgrade | $276.00 |
| May 29, 2025 | Jefferies | David Windley | Hold | Initiates | $263.00 |
| May 19, 2025 | Morgan Stanley | Patrick Wood | Equal-Weight | Maintains | $260.00 |
| May 16, 2025 | JMP Securities | David Turkaly | Market Outperform | Maintains | $280.00 |
| May 15, 2025 | Stephens & Co. | Steven Etoch | Overweight | Reiterates | $250.00 |
| May 12, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Apr 10, 2025 | JMP Securities | David Turkaly | Market Outperform | Reiterates | $265.00 |
| Apr 7, 2025 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Feb 6, 2025 | Stephens & Co. | Jacob Johnson | Overweight | Reiterates | $240.00 |
| Feb 6, 2025 | JMP Securities | Reni Benjamin | Market Outperform | Reiterates | $265.00 |
| Feb 3, 2025 | Piper Sandler | Jason Bednar | Overweight | Maintains | $265.00 |
| Nov 18, 2024 | JMP Securities | David Turkaly | Market Outperform | Reiterates | $265.00 |
| Nov 8, 2024 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Nov 7, 2024 | Stephens & Co. | Jacob Johnson | Overweight | Reiterates | $260.00 |
| Oct 24, 2024 | Piper Sandler | Jason Bednar | Overweight | Upgrade | $260.00 |
| Sep 3, 2024 | Keybanc | Brett Fishbin | Overweight | Maintains | $265.00 |
| Aug 8, 2024 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Aug 7, 2024 | JMP Securities | David Turkaly | Market Outperform | Reiterates | $265.00 |
Steris plc (STE) Competitors
The following stocks are similar to STERIS based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Steris plc (STE) Financial Data
Steris plc has a market capitalization of $21.06B with a P/E ratio of 29.6x. The company generates $5.83B in trailing twelve-month revenue with a 12.1% profit margin.
Revenue growth is +9.2% quarter-over-quarter, while maintaining an operating margin of +18.5% and return on equity of +10.5%.
Valuation Metrics
Market Cap
$21.06B
Enterprise Value
$22.47B
P/E Ratio
29.6x
PEG Ratio
2.5x
Price/Sales
3.6x
Growth & Margins
Revenue Growth (YoY)
+9.2%
Gross Margin
+43.8%
Operating Margin
+18.5%
Net Margin
+12.1%
EPS Growth
+11.2%
Financial Health
Cash/Price Ratio
+2.0%
Current Ratio
2.5x
Debt/Equity
28.7x
ROE
+10.5%
ROA
+6.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Steris plc (STE) Business Model
About Steris plc
What They Do
Provides medical equipment and infection prevention solutions.
Business Model
Steris plc generates revenue through a diverse range of products and services focused on infection prevention and sterilization. The company operates in several segments, including Healthcare Products, Life Sciences, and Applied Sterilization Technologies, catering to various customers such as hospitals and pharmaceutical manufacturers.
Additional Information
With a robust presence in the U.S. market and expanding internationally, Steris plc is committed to enhancing healthcare safety and efficiency. The company's comprehensive offerings include not just equipment, but also vital healthcare services like installation, maintenance, and consulting, establishing it as a key player in the healthcare sector.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
17,787
CEO
Mr. Daniel A. Carestio
Country
United States
IPO Year
1992
Website
www.steris.comSteris plc (STE) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Steris (STE) Down 2.2% Since Last Earnings Report: Can It Rebound?
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mar 06, 2026
By Zacks Equity Research
Realtime BLOG
Latest News
Quick Summary
Steris (STE) reported earnings 30 days ago. Investors should monitor upcoming developments and market reactions for potential impacts on the stock.
Why It Matters
Upcoming earnings reports can significantly affect stock prices. Investors will be closely watching Steris for performance indicators and guidance that could impact future valuations.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Steris (STE) shows notable international revenue trends, influencing Wall Street forecasts and future stock performance. Investors should monitor these developments closely.
Why It Matters
Steris' international revenue trends directly influence earnings forecasts and growth potential, affecting stock valuation and investor sentiment on Wall Street.
Source: Zacks Investment Research
Market Sentiment:
Neutral
STERIS: A Bump In The Road For A Reliable Name
1 month ago
Quick Summary
STERIS reported 8% organic revenue growth but faces margin pressure from tariffs, increasing guidance by $10 million. Stricter EtO regulations may boost outsourcing to its facilities.
Why It Matters
STERIS's strong revenue growth and unique sterilization networks position it well amid regulatory changes, while increasing tariffs may impact margins, affecting overall profitability.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
STERIS plc (STE) held its Q3 2026 earnings call, discussing financial performance and outlook. Further details on revenue and guidance were provided during the call.
Why It Matters
The STERIS plc Q3 2026 earnings call indicates financial performance and future guidance, impacting stock valuation and investor sentiment on growth prospects.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
STERIS plc reported a 9% revenue increase to $1.5 billion for Q3 fiscal 2026, with EPS from continuing operations rising to $1.96 and adjusted EPS to $2.53. Fiscal 2026 outlook maintained.
Why It Matters
Strong revenue growth and increased earnings per share indicate STERIS's solid performance, reassuring investors about the company's stability and growth potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Steris (STE) Meets Q3 Earnings Estimates
1 month ago
Quick Summary
Steris (STE) reported quarterly earnings of $2.53 per share, matching the Zacks Consensus Estimate and up from $2.32 per share in the same quarter last year.
Why It Matters
Steris' earnings meeting expectations and showing year-over-year growth indicates financial stability and potential for continued performance, impacting investor confidence and stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About STE Stock
What is Steris plc's (STE) stock forecast for 2026?
Based on our analysis of 14 Wall Street analysts, Steris plc (STE) has a median price target of $293.00. The highest price target is $300.00 and the lowest is $231.00.
Is STE stock a good investment in 2026?
According to current analyst ratings, STE has 6 Buy ratings, 2 Hold ratings, and 1 Sell ratings. The stock is currently trading at $214.57. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for STE stock?
Wall Street analysts predict STE stock could reach $293.00 in the next 12 months. This represents a 36.6% increase from the current price of $214.57. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Steris plc's business model?
Steris plc generates revenue through a diverse range of products and services focused on infection prevention and sterilization. The company operates in several segments, including Healthcare Products, Life Sciences, and Applied Sterilization Technologies, catering to various customers such as hospitals and pharmaceutical manufacturers.
What is the highest forecasted price for STE Steris plc?
The highest price target for STE is $300.00 from at , which represents a 39.8% increase from the current price of $214.57.
What is the lowest forecasted price for STE Steris plc?
The lowest price target for STE is $231.00 from at , which represents a 7.7% increase from the current price of $214.57.
What is the overall STE consensus from analysts for Steris plc?
The overall analyst consensus for STE is bullish. Out of 14 Wall Street analysts, 6 rate it as Buy, 2 as Hold, and 1 as Sell, with a median price target of $293.00.
How accurate are STE stock price projections?
Stock price projections, including those for Steris plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 15, 2026 8:25 AM UTC